In vivo experiments show that intraperitoneal administration of Lycorine reduces tumor growth in U251-luc intracranially orthotopic transplantation model, EGFR stable knockdown abates Lycorine’s treatment effect in mice subcutenous xenografts, and in patient-derived xenograft model Lycorine exhibits impressive efficacy with no obvious toxicity. The gene discussed is EGFR; the disease is neoplasm.